Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
75.17
+0.14 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
52
53
Next >
Why Is AstraZeneca Stock Trading Lower Today?
October 18, 2023
AstraZeneca Plc (NASDAQ: AZN) shares are trading lower after a data abstract on its experimental drug, datopotamab deruxtecan, for lung cancer patients in a late-stage trial disappointed some...
Via
Benzinga
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock
October 18, 2023
The companies are hoping to use antibody drug conjugates in lung cancer patients.
Via
Investor's Business Daily
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
October 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors
October 16, 2023
Via
Benzinga
AstraZeneca Unusual Options Activity For September 28
September 28, 2023
Via
Benzinga
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 18, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...
Via
Benzinga
Exposures
Product Safety
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
October 16, 2023
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:
Via
Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
October 16, 2023
Benzinga Bitcoin Spiked On False ETF Approval Rumor
Via
Benzinga
Topics
ETFs
AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer
October 16, 2023
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and
Via
Benzinga
Exposures
Product Safety
TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer
October 16, 2023
From
AstraZeneca
Via
Business Wire
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
October 14, 2023
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...
Via
Talk Markets
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition
October 13, 2023
These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.
Via
InvestorPlace
ABBV Stock: Buy for the Yield, Hold for This Other Reason
October 13, 2023
"Safe harbor" status and a high, growing dividend yield isn't the only thing that's appealing with ABBV stock.
Via
InvestorPlace
AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge
October 12, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO
October 11, 2023
From
AstraZeneca
Via
Business Wire
Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity
October 10, 2023
From
AstraZeneca Foundation
Via
Business Wire
2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague
October 06, 2023
Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations.
Via
The Motley Fool
Why Shares of Conduit Pharmaceuticals Are Jumping Wednesday
October 04, 2023
The stock had a brief big rebound from a huge drop on Tuesday.
Via
The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
October 03, 2023
ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive...
Via
Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
October 03, 2023
AstraZeneca Plc (NASDAQ: AZN) has
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
October 02, 2023
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.
Via
Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
September 28, 2023
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.